$2.22
-0.14-5.93%
At close: Aug 14, 5:00 PM EST
Protalix BioTherapeutics Inc Earnings Estimates
PLXAMEX
Earnings: Q2 2026 Earnings were released on Wed Aug 12th, before the market open
Conference Call: The most recent conference call started at 8:00 AM, 4 days agoClick to view the webcast
Protalix BioTherapeutics Earnings Estimates, EPS & Revenue | AMEX:PLX
In the most recent quarter (Q2), Protalix BioTherapeutics reported EPS of $0.05, beating estimates of $-0.01 by 6%. Revenue came in at $19.9M, exceeding the estimate of $12.94M by 0.54%.
Protalix BioTherapeutics has beaten EPS estimates in 2 consecutive quarters.
Over the last 4 quarters, Protalix BioTherapeutics has averaged an EPS surprise of 9.1% and a revenue surprise of 0.71%.
Earnings Date
Aug 12
EPS
$0.050
Quarterly Revenue
$19.9M
Annual Revenue
$80.62M
as of Jun 30
Protalix BioTherapeutics Earnings History
Analyze the earnings history of Protalix BioTherapeutics using advanced sorting and filters.
Protalix BioTherapeutics (PLX) Earnings Per Share
The chart below shows Protalix BioTherapeutics's reported EPS compared to analyst estimates over recent quarters.
Protalix BioTherapeutics (PLX) Revenue
The chart below shows Protalix BioTherapeutics's reported revenue compared to analyst estimates over recent quarters.
FAQ
When is Protalix BioTherapeutics (AMEX:PLX) reporting earnings?
Protalix BioTherapeutics (PLX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on August 12, 2026 for Q2.
What were the latest earnings per share (EPS) for Protalix BioTherapeutics (AMEX:PLX)?
Protalix BioTherapeutics (PLX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on August 12, 2026 for Q2 and the Actual EPS was $0.05, which beat the estimate of $-0.01.
What were Protalix BioTherapeutics’s (AMEX:PLX) revenues?
Protalix BioTherapeutics (PLX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on August 12, 2026 for Q2 and the Actual Revenue was $19.9M, which beat the estimate of $12.94M.
